atrasentan

Known as: (2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid, 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid, atrasentan [Chemical/Ingredient] 
A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists.
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
05101520012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
PURPOSE Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment… (More)
Is this relevant?
2014
2014
Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Although endothelin-receptor antagonists reduce albuminuria in diabetic nephropathy, fluid retention limits their use. Here, we… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Atrasentan is a potent, oral, selective endothelin-A (ET(A)) receptor antagonist that has clinical activity in… (More)
Is this relevant?
2008
2008
Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and… (More)
  • table 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin-A… (More)
Is this relevant?
2007
2007
The effect of rifampin, a cytochrome P450 3A4 inducer, on the pharmacokinetics of atrasentan was assessed in 12 healthy male… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A receptor antagonist, in the treatment of… (More)
Is this relevant?
2003
2003
PURPOSE We examined the effects of atrasentan (endothelin-A receptor antagonist) on bone deposition and resorption markers and on… (More)
Is this relevant?
2002
2002
PURPOSE Endothelin receptors, particularly the ET(A) receptor, have been shown to participate in the pathophysiology of prostate… (More)
Is this relevant?